Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 401-414

  Tummala, Ramakumar ^a,c   Diegelman, Paula ^a   Hector, Suzanne ^b   Kramer, Debora L ^a   Clark, Kimberly ^a   Zagst, Patricia ^a   Fetterly, Gerald ^a   Porter, Carl W ^a   Pendyala, Lakshmi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cisplatin; Diethylnorspermine; Oxaliplatin; Platinum resistance; Polyamines

Indexed keywords

CISPLATIN; MESSENGER RNA; N1,N11 DIETHYLNORSPERMINE; OXALIPLATIN; POLYAMINE DERIVATIVE; SPERMIDINE SYNTHASE; SPERMINE ACETYLTRANSFERASE; SPERMINE SYNTHASE; SULFORHODAMINE B; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; DIAMINE ACETYLTRANSFERASE; DIAMINE N-ACETYLTRANSFERASE; DRUG DERIVATIVE; N(1) ACETYLSPERMIDINE; N(1),N(11) DIETHYLNORSPERMINE; N(1),N(11)-DIETHYLNORSPERMINE; N(1)-ACETYLSPERMIDINE; PLATINUM COMPLEX; POLYAMINE; PUTRESCINE; SPERMIDINE; SPERMINE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG TARGETING; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IC 50; METABOLISM; OVARY TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

ACETYLTRANSFERASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYAMINES; PUTRESCINE; SPERMIDINE; SPERMINE;

EID: 79953794810     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1334-9     Document Type: Article

References (47)

1. Allen WL, McLean EG, Boyer J, McCulla A, Wilson PM, Coyle V, Longley DB, Casero RA Jr, Johnston PG (2007) The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6:128-137 (Pubitemid 46206675)
2. Bergeron RJ, Merriman RL, Olson SG, Wiegand J, Bender J, Streiff RR, Weimar WR (2000) Metabolism and pharmacokinetics of N1, N11-diethylnorspermine in a Cebus apella primate model. Cancer Res 60:4433-4439 (Pubitemid 32103622)
3. Bergeron RJ, Weimar WR, Luchetta G, Streiff RR, Wiegand J, Perrin J, Schreier KM, Porter C, Yao GW, Dimova H (1995) Metabolism and pharmacokinetics of N1, N11-diethylnorspermine. Drug Metab Dispos 23:1117-1125
4. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66:2765-2777
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 52:5115-5118
6. Casero RA, Pegg AE (2009) Polyamine catabolism and disease. Biochem J 421:323-338
7. Casero RA Jr, Pegg AE (1993) Spermidine/spermine N1-acetyltransferase-the turning point in polyamine metabolism. FASEB J 7:653-661 (review) (Pubitemid 23163600)
8. Chen Y, Kramer D, Jell J, Vujcic S, Porter CW (2003) siRNA suppression of polyamine analogue-induced spermidine/spermine N1-acetyltransferase. Mol Pharm 64:1153-1159
9. Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW (2001) Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res 61:6437-6444 (Pubitemid 32783249)
10. Choi W, Gerner EW, Ramdas L, Dupart J, Carew J, Proctor L, Huang P, Zhang W, Hamilton SR (2004) Combination of 5-fluorouracil and N1, N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells. J Biol Chem 280:3295-3304 (Pubitemid 40223791)
11. 11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs 15:227-234 (Pubitemid 27453877)
12. Faessel HM, Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, Greco WR (1998) Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res 58:3036-3050 (Pubitemid 28335085)
13. Faessel HM, Slocum HK, Rustum YM, Greco WR (1999) Folicacidenhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H- pyrimidino[5,4,6][1,4]thiazin - 6-yl) - (S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines. Biochem Pharmacol 57:567-577 (Pubitemid 29073335)
14. Fogel-Petrovic M, Vujcic S, Miller J, Porter CW (1996) Differential post-transcriptional control of orninithine decarboxylase and spermidine-spermine N1-acetyltransferase by polyamines. FEBS Lett 391:89-94 (Pubitemid 26325720)
15. 1-acetyltransferase gene expression. Biochemistry 35:14436-14444 (Pubitemid 26384440)
16. Gessner PK (1974) A straight forward method for the study of drug interactions. In: Morselli PI, Garattini S, Cohen SN (eds) Drug interactions. Raven Press, New York, pp 349-362
17. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16:16-39 (Pubitemid 26033168)
18. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin e (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. [Review] [49 refs]. Clin Cancer Res 6:1205-1218 (Pubitemid 30226200)
19. Hahm HA, Ettinger DS, Bowling K, Hoker B, Chen TL, Zabelina Y, Casero RA Jr (2002) Phase I study of N1, N11-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res 8:684-690 (Pubitemid 34742095)
20. Hawthorne TR, Austin JKJ (1996) Synergism of the polyamine analogue, N1, N11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo. Cancer Lett 99:99-107
21. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406 (Pubitemid 33027997)
22. Hector S, Nava ME, Clark K, Murpy M, Pendyala L (2007) Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett 245:195-204 (Pubitemid 44959353)
23. 1-acetylransferase. Mol Cancer Ther 3:813-822 (Pubitemid 39193763)
24. Hector S, Tummala R, Kisiel ND, Diegelman P, Vujcic S, Clark K, Fakih M, Kramer DL, Porter CW, Pendyala L (2008) Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N (1), N (11) diethylnorspermine. Cancer Chemother Pharmacol 62:517-527
25. Kramer DL, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, McManis JS, Bergeron RJ, Porter CW (1997) Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3 M human melanoma cells. Cancer Res 57:5521-5527 (Pubitemid 28006759)
26. Levi F, Metzger G, Massari C, Milano G (2000) Oxaliplatin: pharmacokietics and chronopharmacological aspects. Clin Pharmacokinet 38:1-21
27. Libby PR, Henderson M, Bergeron RJ, Porter CW (1989) Major increases in spermidine/spermine-N1-acetyltransferase activity by spermine analogues and their relationship to polyamine depletion and growth inhibition in L1210 cells. Cancer Res 49:6226-6231 (Pubitemid 20000913)
28. Marverti G, Bettuzzi S, Astancolle S, Pinna C, Monti MG, Moruzzi MS (2001) Differential induction of spermidine/spermine N1-acetyltransferase activity in cisplatin-sensitive and-resistant ovarian cancer cells in response to N1, N12-bis (ethyl) spermine involves transcriptional and post-transcriptional regulation. Eur J Cancer 37:281-289 (Pubitemid 32144707)
29. Marverti G, Piccinnini G, Ghaironi S, Barbieri D, Quaglino D, Moruzzi MS (1998) N1, N12-Bis (ethyl) spermineeffectongrowth of cis- diamminedichloroplatinum (II)-sensitive and-resistant human ovarian-carcinoma cell lines. Int J Cancer 78:33-40
30. Marverti G, Monti MG, Bettuzzi S, Caporali A, Astancolle S, Moruzzi MS (2004) Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine N (1)-acetyltransferase expression. Int J Biochem Cell Biol 36:123-137 (Pubitemid 37338478)
31. Maxwell P, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin D, Allegra CJ, Johnston PG (2003) Identification of 5-fluorouracil- inducible target genes using cDNA microarray profiling. Cancer Res 63:4602-4606 (Pubitemid 36951036)
32. Paliwal J, Janumpalli G, Basu HS (1998) The mechanism of polyamine analog-induced enhancement of cisplatin cytotoxicity in the U-251 MG human malignant glioma cell line. Cancer Chemother Pharmacol 41:398-402 (Pubitemid 28095756)
33. Pledgie-Tracey A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA, Davidson NE (2009) The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother Pharmacol epub ahead of print 8/30/09
34. Porter C, Herrera-Omelas L, Pera P, Petrelli NF, Mittleman A (1987) Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 60:1275-1281 (Pubitemid 17152906)
35. Porter CW, Ganis B, Libby PR, Bergeron RJ (1991) Correlations between polyamine analogue-induced increases in spermidine/spermine N1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 51:3715-3720
36. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23 (Pubitemid 46137553)
37. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic e (2002) Cellular and molecular pharmacology of oxaliplatin. [Review] [100 refs]. Mol Cancer Ther 1:227-235
38. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S et al (1990) Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Nat Cancer Inst 82:1113-1118 (Pubitemid 20213251)
39. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279 (Pubitemid 37487159)
40. Streiff RR, Bender JF (2001) Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest New Drugs 19:29-39 (Pubitemid 32209783)
41. Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58:244-258 (Pubitemid 32217356)
42. Varma R, Hector S, Greco WR, Clark K, Hawthorn L, Porter C, Pendyala L (2007) Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentrationeffect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 59:711-723 (Pubitemid 46440593)
43. Varma RR, Hector S, Clark K, Greco WR, Hawthorn L, Pendyala L (2005) Gene expression profiling of a clonal isolate of oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14:925-932
44. 1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319-38328 (Pubitemid 32009154)
45. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320 (Pubitemid 41130944)
46. Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero RAJ, Davidson NE (2001) A Phase II study of the polyamine analog N1, N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res 9:5922-5928
47. Zhang W, Ramdas L, Shen W, Song SW, Hu L, Hamilton SR (2003) Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2. Cancer Biol Ther 2:572-578